{"id":992434,"date":"2026-08-10T02:03:06","date_gmt":"2026-08-10T06:03:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/"},"modified":"2026-08-10T02:03:06","modified_gmt":"2026-08-10T06:03:06","slug":"innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/","title":{"rendered":"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma"},"content":{"rendered":"

<\/p>\n

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma<\/b><\/p>\n

MARSEILLE, France–(BUSINESS WIRE<\/a>)–
\nRegulatory News:<\/p>\n

\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) and Swedish Orphan Biovitrum AB (publ) (Sobi\u00ae) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of CTCL.<\/p>\n

\nUnder the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome. The planned TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in S\u00e9zary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialize lacutamab upon potential accelerated approval and will be eligible to assume full global development rights following positive Phase 3 results. Closing of the transaction is subject to closing conditions, including the receipt of transaction related anti-trust clearance.<\/p>\n

\u201cWe are thrilled to partner with Sobi and enable TELLOMAK-3 initiation, the pivotal next step in advancing lacutamab toward a potential accelerated approval in S\u00e9zary syndrome,\u201d said Jonathan Dickinson, CEO of Innate Pharma. <\/b>\u201cSobi is the ideal partner to help unlock the full potential of lacutamab. Their expertise in rare diseases, proven commercial capabilities and global reach perfectly complement Innate\u2019s expertise in CTCL clinical development. Together, we share the ambition to bring lacutamab to patients globally as quickly as possible.\u201d<\/i><\/p>\n

\u201cThis agreement is an important step in strengthening our portfolio and reflects our strategy of partnering with leading innovators to bring differentiated therapies to patients with rare diseases. We look forward to working with Innate Pharma to advance lacutamab and, subject to regulatory approvals, make it available to patients globally,\u201d said Guido Oelkers, President and CEO of Sobi.<\/b><\/i><\/p>\n

Transaction details<\/b><\/p>\n

\nUnder the terms of the agreement, Sobi will pay Innate Pharma USD 75 million, payable on closing. Innate will be eligible to receive up to a further USD 40 million in respect of near-term development milestones connected to S\u00e9zary syndrome. Additionally, Innate will be eligible to receive up to USD 465 million related to the option for Sobi to get full development rights and to future regulatory and commercial milestones. Innate will be eligible to receive tiered double-digit royalties on net sales.<\/p>\n

About Lacutamab<\/b><\/p>\n

\nLacutamab is a first-in-class anti-KIR3DL2 antibody, currently developed in cutaneous T-cell lymphoma (CTCL). CTCL is a group of rare non-Hodgkin lymphomas that includes S\u00e9zary syndrome, a rare and aggressive leukemic form, and mycosis fungoides, the most common subtype in CTCL.<\/p>\n

\nThe program has received Fast Track designation from the FDA, PRIME designation from the EMA for S\u00e9zary syndrome, Orphan Drug designation in both the U.S. and EU for CTCL, and Breakthrough Therapy Designation from the FDA for relapsed or refractory S\u00e9zary syndrome. The program is advancing toward a pivotal Phase 3 TELLOMAK-3 study, an open-label, multicenter, randomized trial in patients with S\u00e9zary syndrome and mycosis fungoides who have failed at least one prior systemic therapy. The study includes a confirmatory cohort in S\u00e9zary syndrome intended to support a potential accelerated approval and upon study completion a full approval for S\u00e9zary syndrome, and a registrational cohort in mycosis fungoides intended to support full approval, with progression-free survival (PFS) as the primary endpoint.<\/p>\n

About Sobi\u00ae<\/b><\/p>\n

\nSobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi\u2019s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com<\/a> and LinkedIn<\/a>.<\/p>\n

About Innate Pharma<\/b><\/p>\n

\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.<\/p>\n

\nInnate Pharma is advancing a portfolio of differentiated potential first- and\/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).<\/p>\n

\nInnate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.<\/p>\n

\nHeadquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n

\nLearn more about Innate Pharma at www.innate-pharma.com<\/a> and follow us on LinkedIn<\/a> and X<\/a>.<\/p>\n

Information about Innate Pharma shares<\/b><\/p>\n

\nISIN code: FR0010331421
\n
Ticker code: Euronext Paris: IPH | Nasdaq: IPHA
\n
LEI: 9695002Y8420ZB8HJE29<\/p>\n

Disclaimer on forward-looking information and risk factors<\/b><\/p>\n

\nFor a discussion of risks and uncertainties, please refer to the Risk Factors (\u201cFacteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website http:\/\/www.amf-france.org<\/a><\/span> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.<\/p>\n

\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260809916851\/en\/<\/a><\/span><\/p>\n

\nSt\u00e9phanie Cornen
\n
VP, Investor Relations & Corporate Communications
\n
stephanie.cornen@innate-pharma.fr<\/a><\/p>\n

\nInvestor Relations
\n
investors@innate-pharma.fr<\/a><\/p>\n

\nMedia
\n
communication@innate-pharma.fr<\/a><\/p>\n

KEYWORDS:<\/b> France Europe<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma MARSEILLE, France–(BUSINESS WIRE)– Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) and Swedish Orphan Biovitrum AB (publ) (Sobi\u00ae) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome. The planned TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in S\u00e9zary syndrome … <\/p>\n

Continue reading “Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-992434","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nInnate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma MARSEILLE, France–(BUSINESS WIRE)– Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) and Swedish Orphan Biovitrum AB (publ) (Sobi\u00ae) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome. The planned TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in S\u00e9zary syndrome … Continue reading "Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T06:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260809916851r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma\",\"datePublished\":\"2026-08-10T06:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/\"},\"wordCount\":1063,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260809916851r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/\",\"name\":\"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260809916851r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-08-10T06:03:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260809916851r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260809916851r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma - Market Newsdesk","og_description":"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma MARSEILLE, France–(BUSINESS WIRE)– Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) and Swedish Orphan Biovitrum AB (publ) (Sobi\u00ae) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome. The planned TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in S\u00e9zary syndrome … Continue reading \"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-10T06:03:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260809916851r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma","datePublished":"2026-08-10T06:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/"},"wordCount":1063,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260809916851r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/","name":"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260809916851r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-08-10T06:03:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260809916851r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260809916851r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-enters-strategic-partnership-with-sobi-to-license-lacutamab-in-t-cell-lymphoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=992434"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992434\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=992434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=992434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=992434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}